期刊
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 6, 期 6, 页码 805-824出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14787210.6.6.805
关键词
cephalosporin; ESBL; extended-spectrum beta-lactamase; susceptibility
资金
- NIAID NIH HHS [R01 AI063517, R01-AI063517, R01 AI063517-04] Funding Source: Medline
Cefepime is a 'fourth-generation' cephalosporin with an in vitro extended-spectrum of activity against Gram-negative and Gram-positive pathogens. Cefepime is approved for the treatment of moderate-to-severe infections, such as pneumonia, uncomplicated and complicated urinary tract infections, skin and soft-tissue infections, intra-abdominal infections and febrile neutropenia. In this article, we provide a critical review of pharmacodynamics, clinical management, pharmacokinetics, metabolism, pharmacodynamic target analyses, clinical efficacy, safety and tolerability of cefepime after more than a decade of clinical use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据